3 results
Primary objective: To investigate whether pharmacokinetics of the recommended dose of inhaled tobramycin, defined as serum tobramycin Area Under the Curve (AUC0-24hr), with the I-neb (75 mg) is equivalent to the PariLCPlus (300 mg) nebuliser inā¦
Primary objective: To determine the safety of once daily inhalation of the recommended daily dose of tobramycin with the AkitaĀ® and the PARI-LCĀ® Plus nebulizer in patients with CF. Systemic absorption can be used as surrogate parameter for safety.ā¦
To assess the efficacy of the co-administration of lanreotide Autogel 120 mg(administered via deep sub-cutaneous injections every 28 days) and pegvisomant(administered at 40 to 120 mg per week via sub-cutaneous injection given once ortwice a week)ā¦